Aduro registers $86.25 million of stock for initial public offering

Bookrunners BofA Merrill Lynch and Leerink Partners assist with sale

By Devika Patel

Knoxville, Tenn., March 11 – Aduro Biotech, Inc. will conduct an initial public sale of common stock with a 30-day greenshoe, according to an S-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $86.25 million of stock.

BofA Merrill Lynch and Leerink Partners LLC are the bookrunning managers. William Blair & Co., LLC and Canaccord Genuity Inc. are the co-managers.

Proceeds will be used for clinical trials, manufacturing, research and development and general corporate and working capital purposes.

The clinical-stage immuno-oncology company is based in Berkeley, Calif. The company expects its shares will trade on the Nasdaq under the symbol “ADRO.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.